Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Inventiva, NovAliX establish strategic alliance
May 2013
SHARING OPTIONS:

STRASBOURG, France—A strategic alliance has been announced between Inventiva and NovAliX, under which the partners will focus on discovering clinical candidates that target nuclear receptors. The alliance allows Inventiva and NovAliX to provide a set of fully integrated nuclear drug discovery capabilities, from target validation to the Investigational New Drug stage, as a single unit, and will leverage both companies' proprietary libraries.
 
"This is a great opportunity for pharmaceutical and biotech companies wishing to engage in discovery collaborations to address this major, therapeutically relevant target class. Based on our unique drug discovery platform, proven track record in nuclear receptors and our experience in managing collaborations, I strongly believe in our ability to again deliver innovative drug development candidates to our partners," Pierre Broqua, chief scientific officer and co-founder of Inventiva, said in a press release.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.